Research guide · Metabolic Support
SLU-PP-332 — research protocol
Pan-ERR agonist studied as an 'exercise mimetic' for mitochondrial biogenesis, fat oxidation and endurance.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Pan-ERR (estrogen-related receptor) agonist
- Studied for fat oxidation and endurance capacity
- Lyophilized powder for stability
- 99% HPLC verified purity
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
SLU-PP-332 is a synthetic small-molecule pan-agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ), often described as an exercise mimetic. It is not FDA-approved and has no human clinical trial program as of June 2026; all published in-vivo doses are for mice.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Mid-dose (Oral) | 25 mg (½ tablet) | Once daily | Not specified; ~120 days from one 60-tablet bottle | Oral |
| Standard supplier-tablet dose (Oral) | 50 mg (1 tablet) | Once daily | Not specified; ~60 days from one bottle | Oral |
| Higher community pattern (Oral) | 100 mg (2 tablets) | Once or split twice daily | Not specified; ~30 days from one bottle | Oral |
| Published Murine Regimen (Billon 2023 — endurance) | 25 mg/kg | Once daily | 15 days | IP |
Cycle: Community oral protocols often use 8-12 weeks on and 4 weeks off, but the rationale for cycling is theoretical.
Benefits and research observations: Mouse studies showed acute aerobic exercise transcriptional signature within hours, increased treadmill endurance in 15 days, and reduced fat mass or improved metabolic markers in 28 days.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Billon C, et al. J Pharmacol Exp Ther, 2023.
- 2.Burris TP, et al. Cell Metab, 2024.